OBJECTIVES: To investigate the influence of comorbidities on treatment modalities of colorectal cancer according to the age of patients and French recommendations. DESIGN: Population-based study SETTING: French Digestive Cancer Registry, Burgundy. PARTICIPANTS: Two thousand nine hundred twenty-one incident colorectal cancers diagnosed between 2004 and 2007. MEASUREMENTS: The independent influence of comorbidities (recorded according to the Charlson index) on treatment was analyzed using multivariate logistic regressions controlling for age, sex, and their interaction. RESULTS: The association between comorbidities and resection for cure was significant only in patients younger than 75 (P interaction=.008). For Stage III colon cancer, 40.4% of the patients aged 75 and older had adjuvant chemotherapy, versus 90.5% of those younger than 75 (P<.001). The association between comorbidities and adjuvant chemotherapy for Stage III colon cancer was significant only in patients younger than 75 (P interaction=.004). Patients aged 75 and older were less likely to receive chemotherapy, even when they had few or no comorbidities. Overall, 29.3% of patients aged 75 and older with advanced colorectal cancer had palliative chemotherapy, versus 77.1% of those younger than 75 (P<.001). Whatever the age, palliative chemotherapy was less frequent for a Charlson comorbidity index of 2 or greater (P interaction=.16). Radiotherapy was administered in 59.0% of patients aged 75 and older with rectal cancer, versus 85.3% of those younger than 75 (P<.001). Whatever the age, patients with a Charlson score of 2 or greater were less likely to receive radiotherapy for rectal cancer than were patients without comorbidities (P interaction=.86). CONCLUSION: Further studies are warranted to identify more precisely the reasons for lower treatment rates for colorectal cancer in the older population.
OBJECTIVES: To investigate the influence of comorbidities on treatment modalities of colorectal cancer according to the age of patients and French recommendations. DESIGN: Population-based study SETTING: French Digestive Cancer Registry, Burgundy. PARTICIPANTS: Two thousand nine hundred twenty-one incident colorectal cancers diagnosed between 2004 and 2007. MEASUREMENTS: The independent influence of comorbidities (recorded according to the Charlson index) on treatment was analyzed using multivariate logistic regressions controlling for age, sex, and their interaction. RESULTS: The association between comorbidities and resection for cure was significant only in patients younger than 75 (P interaction=.008). For Stage III colon cancer, 40.4% of the patients aged 75 and older had adjuvant chemotherapy, versus 90.5% of those younger than 75 (P<.001). The association between comorbidities and adjuvant chemotherapy for Stage III colon cancer was significant only in patients younger than 75 (P interaction=.004). Patients aged 75 and older were less likely to receive chemotherapy, even when they had few or no comorbidities. Overall, 29.3% of patients aged 75 and older with advanced colorectal cancer had palliative chemotherapy, versus 77.1% of those younger than 75 (P<.001). Whatever the age, palliative chemotherapy was less frequent for a Charlson comorbidity index of 2 or greater (P interaction=.16). Radiotherapy was administered in 59.0% of patients aged 75 and older with rectal cancer, versus 85.3% of those younger than 75 (P<.001). Whatever the age, patients with a Charlson score of 2 or greater were less likely to receive radiotherapy for rectal cancer than were patients without comorbidities (P interaction=.86). CONCLUSION: Further studies are warranted to identify more precisely the reasons for lower treatment rates for colorectal cancer in the older population.
Authors: Christina Sinding; Rachel Warren; Donna Fitzpatrick-Lewis; Jonathan Sussman Journal: Support Care Cancer Date: 2014-08-14 Impact factor: 3.603
Authors: Sunny Wang; Melisa L Wong; Nathan Hamilton; J Ben Davoren; Thierry M Jahan; Louise C Walter Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: Anne Kaufmann; Heike Schmidt; Christian Ostheimer; Janine Ullrich; Margarete Landenberger; Dirk Vordermark Journal: Support Care Cancer Date: 2014-12-06 Impact factor: 3.603
Authors: Michelle Y Martin; Mona N Fouad; Robert A Oster; Deborah Schrag; Julie Urmie; Sara Sanders; Maria Pisu Journal: Support Care Cancer Date: 2013-09-14 Impact factor: 3.603
Authors: Mina S Sedrak; Rachel A Freedman; Harvey J Cohen; Hyman B Muss; Aminah Jatoi; Heidi D Klepin; Tanya M Wildes; Jennifer G Le-Rademacher; Gretchen G Kimmick; William P Tew; Kevin George; Simran Padam; Jennifer Liu; Andrew R Wong; Andrea Lynch; Benjamin Djulbegovic; Supriya G Mohile; William Dale Journal: CA Cancer J Clin Date: 2020-10-01 Impact factor: 508.702